2023-507661-26-00CompletedPhase 1
A PHASE 1, OPEN-LABEL, RANDOMIZED, THREE-PERIOD, THREE-TREATMENT, BALANCED, SIX-SEQUENCE CROSSOVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF DIFFERENT HYDROMETHYLTHIONINE MESYLATE (HMTM) TABLET FORMULATIONS AND STRENGTHS IN HEALTHY ADULT SUBJECTS.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 31 Jan 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 18 Dec 2023
- Start date
- 18 Mar 2024
- Lead sponsor
- Taurx Therapeutics Limited
- EU CT number
- 2023-507661-26-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 24
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.